Big pharmaceutical companies are often plagued by patent expirations on major products.That doesn't mean you should stop investing in them,prominent money manager and commentator Alan Lancz(pronounced Lance)points out.A frequent guest on business television,Mr.Lancz likes drugmakers Pfizer and Merck at this time.
Pfizer and Merck offer good dividend yields.As well,while stock analysts focus on their patent expirations,you don't often hear about their acquisitions or drug pipelines,such as Pfizer's acquisition of Wyeth and King Pharmaceuticals.
In the case of medical device maker Hologic,Mr.Lancz feels it's a bit toppy right now,but should be purchased at the buy limit of 17.00 or below.It closed at 17.55 on Thursday.
Hologic develops,manufactures and supplies diagnostics,medical imaging systems and surgical products for women's health needs,such as breast health products and GYN surgical products.
Alan B. Lancz is publisher of The Lancz Letter,a subscription-only newsletter that gives current recommendations and analysis on stocks,bonds,real estate,currencies and other related investment vehicles.
Pfizer(PFE),Merck(MRK),Hologic(HOLX)
No comments:
Post a Comment